Bivalent BA.4/BA.5 COVID-19 booster vaccines well tolerated
New vaccine safety data published by AusVaxSafety have shown Australians report fewer side effects following COVID-19 vaccination with the newly introduced bivalent BA.4/BA.5 booster vaccines than with the existing bivalent BA.1 and original COVID-19 booster vaccines.
Most participants experienced no side effects in the first three days following Pfizer bivalent BA.4/BA.5 (73 per cent) and Moderna bivalent BA.4/BA.5 (64 per cent) COVID-19 vaccination.
Study: COVID-19 vaccination highly effective against death in older Australians
A new national study of 3.8 million adults has shown that in Australian adults aged 65 years and older, recent COVID-19 vaccination – a booster dose received in the last three months – reduced the risk of death from SARS-CoV-2 infection by as much as 93 per cent compared to those who were unvaccinated.
The benefit was particularly high for adults resident in aged care facilities, who have significantly higher COVID-19 mortality rates. Between June and November 2022, one COVID-19 death was prevented among aged care residents for every 157 people boosted.
Analysis of vaccine recipients during the first omicron wave found vaccine effectiveness against COVID-19 death was highest (93 per cent) in the three months following a third COVID-19 vaccine dose; effectiveness decreased (to 63 per cent) in individuals who had received their third COVID-19 vaccine dose more than six months prior.
Similarly, during the second omicron wave, vaccine effectiveness against COVID-19 death was highest (84 per cent) in individuals in the three months following a fourth COVID-19 vaccine dose, and effectiveness decreased (to 56 per cent) in those who had received their fourth dose more than six months prior.
Australia’s Chief Medical Officer, Professor Paul Kelly, said, “These findings confirm that current recommendations for a COVID-19 booster to be given when it has been more than six months since last receipt (or infection) are important to protect older adults against death from COVID-19, particularly for aged care residents.’’
Updates to COVID-19 resources
Immunisation providers are strongly advised to access these resources via the online links, as they are updated regularly, and information can quickly become outdated and incorrect.
COVID-19 Vaccines in Australia
This poster provides key differences between each COVID-19 vaccine approved for use in Australia as per the Australian Technical Advisory Group on Immunisation (ATAGI) guidelines.
ATAGI recommended COVID-19 vaccine doses – updated 4 May
This poster outlines the COVID-19 vaccine doses recommended for each age and population group.
Cold Chain Breach (CCB) reporting form – updated 4 May
This form is to help vaccine providers report a potential cold chain breach under the COVID-19 vaccination program.
Immunisation Education
Webinar: PenCS – Increase influenza immunisation coverage in your practice
About: Learn how to use the FLU Topbar App and how to identify patients eligible for the NIP funded flu vaccine
Watch the webinar recording on human papillomavirus (HPV) vaccination, including an in-depth look at the use, effectiveness and safety of HPV vaccines.
Maroubra Medicare Urgent Care Clinic (UCC) is now open The Maroubra Medicare Urgent Care Clinic (UCC) is now open, seven days a week, from 8.00am to 8.00pm. It was officially launched by member for Kingsford Smith, the hon Matt Thistlethwaite MP (pictured at the launch with CESPHN CEO Nathalie Hansen…
Media Release: Central and Eastern Sydney PHN releases Healthy Ageing Strategy to empower older people In response to the increasing longevity and rapid growth of the older population the Central and Eastern Sydney Primary Health Network (CESPHN) is proud to release its new Healthy Ageing Strategy 2023-2028. This comprehensive strategy…
Immunisation Weekly Update: COVID-19 XBB.1.5 vaccine onboarding The Australian Government has accepted the latest advice from ATAGI on the use of the new COVID-19 XBB 1.5 vaccine as part of the National COVID-19 Vaccine Program. All sites currently participating in the COVID-19 Vaccination Program will be onboarded for the three…
Immunisation Weekly Update: Increase in COVID-19 infection cases ATAGI notes a recent increase in COVID-19 cases since November 2023 across Australia and encourages all eligible people who have not yet had their recommended 2023 COVID-19 vaccine dose/s to receive them as soon as possible. A first 2023 dose is recommended…
Immunisation Weekly Update: Vaccination coverage in RACF Australian Immunisation Register (AIR) data suggests that only 36% of people aged 70+ living in the central and eastern Sydney PHN region are immunised against Pneumococcal diseases. Immunisation providers are reminded to check AIR immunisation history statements of patients going into Residential Aged…
Immunisation Weekly Update: Introduction of Shingrix® to the NIP From 1 November 2023, the shingles vaccine Shingrix® will replace Zostavax® on the National Immunisation Program (NIP) schedule for the prevention of shingles and post-herpetic neuralgia. It will be available for eligible people most at risk of complications from shingles. A…
Continuing Professional Development (CPD) annual requirements Below is a snapshot of the continuing professional development (CPD) requirements for doctors, these include annual requirements of: completion of a Professional Development Plan 50 hours CPD each year, split across a range of activities: 25 hours – reviewing performance and measuring outcomes (with five hours minimum…
CESPHN’s Annual Report 2022-23 is now live Central and Eastern Sydney PHN has released its Annual Report 2022-23. The Annual Report is a summary of the key achievements and highlights for the PHN over the financial year. It is split into Improving Care Integration, Improving Practice and Commissioning Services to…